Entos is now Iambic Therapeutics
Read more
Platform
Pipeline
Partnerships
News & Media
About
Careers
Contact
Contact
Presentations
back to blog
AI-driven discovery of 1000-fold selective and CNS-penetrant Her2 inhibitor
Presentations
This is some text inside of a div block.
January 31, 2024
Media Contacts
Related announcements
View All
View All
September 27, 2024
Iambic Therapeutics Named to the Endpoints 11 List of Biotech’s Most Promising Startups
Read more
September 27, 2024
Iambic Therapeutics Named to the Endpoints 11 List of Biotech’s Most Promising Startups
Read more
September 26, 2024
Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery
Read more
September 26, 2024
Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery
Read more
September 5, 2024
Iambic Therapeutics Announces the Addition of Dr. Mary Tagliaferri to its Board of Directors
Read more
September 5, 2024
Iambic Therapeutics Announces the Addition of Dr. Mary Tagliaferri to its Board of Directors
Read more